IDEAYA Biosciences (IDYA) said Thursday it has signed an additional clinical trial collaboration and supply agreement with Gilead Sciences (GILD) to assess the efficacy and safety of IDE397 plus Gilead's Trodelvy in methylthioadenosine phosphorylase-deletion, or MTAP-deletion, non-small cell lung cancer.
The drugmakers will include patients with lung cancer in an ongoing phase 1 trial evaluating the combination regimen in MTAP-deletion urothelial cancer, with clinical updates expected this year, IDEAYA Chief Medical Officer Darrin Beaupre said.
IDEAYA said it is currently enrolling patients in a monotherapy expansion in lung and urothelial cancer and is projecting to begin a combination trial of IDE397 and IDE892 in H2.
Shares of IDEAYA fell 4.1%, while Gilead rose 2.2% in recent trading.
Price: 21.06, Change: -0.89, Percent Change: -4.05
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。